When building a strong brand identity, your logo is the star of the show. It’s often the first thing customers see, recognize ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares closed today ...

Learn More Pharmaceutical giant GSK is pushing the boundaries of what generative AI can achieve in healthcare areas like scientific literature review, genomic analysis and drug discovery.

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price target of £23.55. The company’s shares closed ...

A high-profile team of architects, landscape designers, and consultants has been appointed to progress a masterplan for the redevelopment of the former GSK headquarters at 980 Great West Road, ...

Last month saw a number of alliances forming in a range of therapeutic spaces but there has been one serial collaborator that stands out – GSK. The British pharma giant seems to have embarked on a ...